Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate

Nasir Ud Din, Asim Qureshi, Samina Mansoor

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder are common cancers in men. High grade forms of these tumors may present ambiguous morphologic features that do not permit a definite diagnosis. This distinction between the two tumors has significant staging and therapeutic implications. Hence, an accurate diagnosis is essential for optimal patient care. p63 is a new marker which can be used in this context. It is expressed in most of the urothelial carcinomas and negative in majority of prostatic adenocarcinomas. Aim: To compare the expression of p63 in urothelial carcinomas and adenocarcinomas of prostate. Materials and Methods: Comparative cross - sectional study was carried out at a tertiary cancer hospital from 15 June 2006 to 15 December 2006. Immunohistochemical stain p63 was performed on 50 cases of urothelial carcinoma and 50 prostatic adenocarcinomas. Patients' name, age, histology numbers, grade of tumor, and expression of p63 were recorded. p63 expression was seen in 44 of 50 urothelial carcinomas (88%). None of the prostatic adenocarcinomas expressed p63. The ages of patients with prostatic adenocarcinoma ranged from 49 to 86 years with a median age of 71 years and 41 to 83 years for urothelial carcinomas with a median age of 60.5 years. Conclusion: p63 can be used as a reliable marker to distinguish prostatic adenocarcinomas from urothelial carcinomas in difficult cases in conjunction with other markers like PSA.

Original languageEnglish
Pages (from-to)59-62
Number of pages4
JournalIndian Journal of Pathology and Microbiology
Volume54
Issue number1
DOIs
Publication statusPublished - Jan 2011

Fingerprint

Prostate
Adenocarcinoma
Coloring Agents
Carcinoma
Cancer Care Facilities
Neoplasms
Urinary Bladder Neoplasms
Tertiary Care Centers
Names
Histology
Patient Care
Cross-Sectional Studies

Keywords

  • p63
  • prostate
  • prostatic adenocarcinomas
  • urinary bladder
  • urothelial carcinomas

ASJC Scopus subject areas

  • Pathology and Forensic Medicine
  • Microbiology (medical)

Cite this

Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate. / Ud Din, Nasir; Qureshi, Asim; Mansoor, Samina.

In: Indian Journal of Pathology and Microbiology, Vol. 54, No. 1, 01.2011, p. 59-62.

Research output: Contribution to journalArticle

@article{2040c9b1da7544728baac31d1eb88bb1,
title = "Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate",
abstract = "Background: Prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder are common cancers in men. High grade forms of these tumors may present ambiguous morphologic features that do not permit a definite diagnosis. This distinction between the two tumors has significant staging and therapeutic implications. Hence, an accurate diagnosis is essential for optimal patient care. p63 is a new marker which can be used in this context. It is expressed in most of the urothelial carcinomas and negative in majority of prostatic adenocarcinomas. Aim: To compare the expression of p63 in urothelial carcinomas and adenocarcinomas of prostate. Materials and Methods: Comparative cross - sectional study was carried out at a tertiary cancer hospital from 15 June 2006 to 15 December 2006. Immunohistochemical stain p63 was performed on 50 cases of urothelial carcinoma and 50 prostatic adenocarcinomas. Patients' name, age, histology numbers, grade of tumor, and expression of p63 were recorded. p63 expression was seen in 44 of 50 urothelial carcinomas (88{\%}). None of the prostatic adenocarcinomas expressed p63. The ages of patients with prostatic adenocarcinoma ranged from 49 to 86 years with a median age of 71 years and 41 to 83 years for urothelial carcinomas with a median age of 60.5 years. Conclusion: p63 can be used as a reliable marker to distinguish prostatic adenocarcinomas from urothelial carcinomas in difficult cases in conjunction with other markers like PSA.",
keywords = "p63, prostate, prostatic adenocarcinomas, urinary bladder, urothelial carcinomas",
author = "{Ud Din}, Nasir and Asim Qureshi and Samina Mansoor",
year = "2011",
month = "1",
doi = "10.4103/0377-4929.77326",
language = "English",
volume = "54",
pages = "59--62",
journal = "Indian Journal of Pathology and Microbiology",
issn = "0377-4929",
publisher = "Medknow Publications and Media Pvt. Ltd",
number = "1",

}

TY - JOUR

T1 - Utility of p63 immunohistochemical stain in differentiating urothelial carcinomas from adenocarcinomas of prostate

AU - Ud Din, Nasir

AU - Qureshi, Asim

AU - Mansoor, Samina

PY - 2011/1

Y1 - 2011/1

N2 - Background: Prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder are common cancers in men. High grade forms of these tumors may present ambiguous morphologic features that do not permit a definite diagnosis. This distinction between the two tumors has significant staging and therapeutic implications. Hence, an accurate diagnosis is essential for optimal patient care. p63 is a new marker which can be used in this context. It is expressed in most of the urothelial carcinomas and negative in majority of prostatic adenocarcinomas. Aim: To compare the expression of p63 in urothelial carcinomas and adenocarcinomas of prostate. Materials and Methods: Comparative cross - sectional study was carried out at a tertiary cancer hospital from 15 June 2006 to 15 December 2006. Immunohistochemical stain p63 was performed on 50 cases of urothelial carcinoma and 50 prostatic adenocarcinomas. Patients' name, age, histology numbers, grade of tumor, and expression of p63 were recorded. p63 expression was seen in 44 of 50 urothelial carcinomas (88%). None of the prostatic adenocarcinomas expressed p63. The ages of patients with prostatic adenocarcinoma ranged from 49 to 86 years with a median age of 71 years and 41 to 83 years for urothelial carcinomas with a median age of 60.5 years. Conclusion: p63 can be used as a reliable marker to distinguish prostatic adenocarcinomas from urothelial carcinomas in difficult cases in conjunction with other markers like PSA.

AB - Background: Prostatic adenocarcinoma and urothelial carcinoma of the urinary bladder are common cancers in men. High grade forms of these tumors may present ambiguous morphologic features that do not permit a definite diagnosis. This distinction between the two tumors has significant staging and therapeutic implications. Hence, an accurate diagnosis is essential for optimal patient care. p63 is a new marker which can be used in this context. It is expressed in most of the urothelial carcinomas and negative in majority of prostatic adenocarcinomas. Aim: To compare the expression of p63 in urothelial carcinomas and adenocarcinomas of prostate. Materials and Methods: Comparative cross - sectional study was carried out at a tertiary cancer hospital from 15 June 2006 to 15 December 2006. Immunohistochemical stain p63 was performed on 50 cases of urothelial carcinoma and 50 prostatic adenocarcinomas. Patients' name, age, histology numbers, grade of tumor, and expression of p63 were recorded. p63 expression was seen in 44 of 50 urothelial carcinomas (88%). None of the prostatic adenocarcinomas expressed p63. The ages of patients with prostatic adenocarcinoma ranged from 49 to 86 years with a median age of 71 years and 41 to 83 years for urothelial carcinomas with a median age of 60.5 years. Conclusion: p63 can be used as a reliable marker to distinguish prostatic adenocarcinomas from urothelial carcinomas in difficult cases in conjunction with other markers like PSA.

KW - p63

KW - prostate

KW - prostatic adenocarcinomas

KW - urinary bladder

KW - urothelial carcinomas

UR - http://www.scopus.com/inward/record.url?scp=79952975078&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952975078&partnerID=8YFLogxK

U2 - 10.4103/0377-4929.77326

DO - 10.4103/0377-4929.77326

M3 - Article

VL - 54

SP - 59

EP - 62

JO - Indian Journal of Pathology and Microbiology

JF - Indian Journal of Pathology and Microbiology

SN - 0377-4929

IS - 1

ER -